Saturday, July 11, 2026

Drug profile · INN

semuloparin sodium

semuloparin sodium (MULSEVO) is a antithrombin-iii inhibitor.

EMA: application withdrawn
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — semuloparin sodium
Class
Route
Patents
0
Programs
1
Data quality
0.83

Quick answer

semuloparin sodium (MULSEVO) is a antithrombin-iii inhibitor.

Key facts

INN semuloparin sodium
Brand MULSEVO
Mechanism Antithrombin-III inhibitor
Target Antithrombin-III

Mechanism of action

Antithrombin-III inhibitor

Primary target: Antithrombin-III

Approval history

Authority Status Date
EMA application withdrawn

Pipeline programs

  1. Semuloparin sodium Phase 3 · Sanofi Pasteur MSD · Venous Thromboembolism

Related & competitor drugs

  1. enoxaparin sodium Blood and blood forming organs (B01)
  2. fondaparinux sodium Blood and blood forming organs (B01)
  3. heparin sodium Antithrombin-III activator
  4. ardeparin sodium Antithrombin-III activator
  5. dalteparin sodium Antithrombin-III activator
  6. danaparoid sodium Antithrombin-III activator

Frequently asked questions

What is semuloparin sodium?

semuloparin sodium (MULSEVO) is a antithrombin-iii inhibitor.

What is the brand name for semuloparin sodium?

MULSEVO is a marketed brand name for semuloparin sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.